Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (34)
Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu & Hua Peng. (2023) Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 72:8, pages 1544-1554.
Crossref
Crossref
Harry L.A. Janssen, Jurrien Reijnders & Milan Sonneveld. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
485
500.e5
.
X. Chuai, P. Chen, H. Chen, W. Wang, Y. Deng, L. Ruan, W. Li & W. Tan. (2017) Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens. Journal of Viral Hepatitis 24:4, pages 337-345.
Crossref
Crossref
Haley Ward, Lydia Tang, Bhawna Poonia & Shyam Kottilil. (2016) Treatment of hepatitis B virus: an update. Future Microbiology 11:12, pages 1581-1597.
Crossref
Crossref
Ruma Rajbhandari & Raymond T Chung. (2016) Treatment of Hepatitis B: A Concise Review. Clinical and Translational Gastroenterology 7:9, pages e190.
Crossref
Crossref
Danming Zhu, Longchao Liu, Dan Yang, Sherry Fu, Yingjie Bian, Zhichen Sun, Junming He, Lishan Su, Liguo Zhang, Hua Peng & Yang-Xin Fu. (2016) Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. The Journal of Immunology 196:7, pages 3079-3087.
Crossref
Crossref
Simone Backes, Clemens Jäger, Claudia J. Dembek, Anna D. Kosinska, Tanja Bauer, Ann-Sophie Stephan, Andris Dišlers, George Mutwiri, Dirk H. Busch, Lorne A. Babiuk, Georg Gasteiger & Ulrike Protzer. (2016) Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine 34:7, pages 923-932.
Crossref
Crossref
Mayur Brahmania, Jordan Feld, Ambreen Arif & Harry L A Janssen. (2016) New therapeutic agents for chronic hepatitis B. The Lancet Infectious Diseases 16:2, pages e10-e21.
Crossref
Crossref
Debin Yu, Hong Liu, Shuai Shi, Liwei Dong, Hongge Wang, Nuoting Wu, Hui Gao, Zhaojun Cheng, Qun Zheng, Jiaojiao Cai, Libo Zou & Zhihua Zou. (2015) A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice. Immunology Letters 168:2, pages 293-299.
Crossref
Crossref
Jinhong Chang & Ju-Tao Guo. (2015) Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Research 121, pages 152-159.
Crossref
Crossref
Adam J. Gehring & June Ann D'Angelo. (2014) Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cellular & Molecular Immunology 12:3, pages 283-291.
Crossref
Crossref
Yun Bin Lee, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon & Hyo-Suk Lee. (2015) The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. Journal of Medical Virology 87:4, pages 575-582.
Crossref
Crossref
Daniel Shouval, Hedwig Roggendorf & Michael Roggendorf. (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine. Medical Microbiology and Immunology 204:1, pages 57-68.
Crossref
Crossref
Jing Zheng, Liping Hu, Min Zhang, Jingli Xu & Pingang He. (2015) An electrochemical sensing strategy for the detection of the hepatitis B virus sequence with homogenous hybridization based on host–guest recognition. RSC Advances 5:112, pages 92025-92032.
Crossref
Crossref
Antonio Bertoletti & Laura Rivino. (2014) Hepatitis B. Current Opinion in Infectious Diseases 27:6, pages 528-534.
Crossref
Crossref
David Gordon, Peter Kelley, Susanne Heinzel, Peter Cooper & Nikolai Petrovsky. (2014) Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study. Vaccine 32:48, pages 6469-6477.
Crossref
Crossref
Jinhong Chang, Fang Guo, Xuesen Zhao & Ju-Tao Guo. (2014) Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharmaceutica Sinica B 4:4, pages 248-257.
Crossref
Crossref
Y Lobaina & JC Aguilar. (2013) Immunotherapy for Chronic Hepatitis B using
HBsAg-based Vaccine Formulations: From Preventive
Commercial Vaccines to Therapeutic Approach. Euroasian Journal of Hepato-Gastroenterology 4:2, pages 92-97.
Crossref
Crossref
Rama Kapoor & Shyam Kottilil. (2014) Strategies to eliminate HBV infection. Future Virology 9:6, pages 565-585.
Crossref
Crossref
N Obeng-Adjei, N A Hutnick, J Yan, J S Chu, D J F Myles, M P Morrow, N Y Sardesai & D B Weiner. (2013) DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Therapy 20:12, pages 652-662.
Crossref
Crossref
Antonio Bertoletti & Carlo Ferrari. (2013) Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgraduate Medical Journal 89:1051, pages 294-304.
Crossref
Crossref
Fadi Saade, Yoshikazu Honda-Okubo, Samay Trec & Nikolai Petrovsky. (2013) A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31:15, pages 1999-2007.
Crossref
Crossref
Xia Chuai, Hong Chen, Wen Wang, Yao Deng, Bo Wen, Li Ruan & Wenjie Tan. (2013) Poly(I:C)/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine Boosting. PLoS ONE 8:1, pages e54126.
Crossref
Crossref
Dimitra Peppa & Mala K Maini. (2012) Pathogenesis of hepatitis B virus infection and potential for new therapies. British Journal of Hospital Medicine 73:10, pages 581-584.
Crossref
Crossref
Zheng Zhang, Ji-Yuan Zhang, Li-Feng Wang & Fu-Sheng Wang. (2012) Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology 27:2, pages 223-230.
Crossref
Crossref
G. Nebbia, D. Peppa & M. K. Maini. (2012) Hepatitis B infection: current concepts and future challenges. QJM 105:2, pages 109-113.
Crossref
Crossref
Hong Chen, Bo Wen, Yao Deng, Wen Wang, Xiao Yin, Jie Guan, Li Ruan & Wenjie Tan. (2011)
Enhanced Effect of DNA Immunization plus
In Vivo
Electroporation with a Combination of Hepatitis B Virus Core-PreS1 and S-PreS1 Plasmids
. Clinical and Vaccine Immunology 18:11, pages 1789-1795.
Crossref
Crossref
Marie-Louise Michel, Qiang Deng & Maryline Mancini-Bourgine. (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges. Journal of Hepatology 54:6, pages 1286-1296.
Crossref
Crossref
John D. Morrey, Neil E. Motter, Stella Chang & Jeffery Fairman. (2011) Breaking B and T cell tolerance using cationic lipid–DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Research 90:3, pages 227-230.
Crossref
Crossref
Daniel Grimm, Robert Thimme & Hubert E. Blum. (2011) HBV life cycle and novel drug targets. Hepatology International 5:2, pages 644-653.
Crossref
Crossref
U. Protzer & H. Abken. (2010) Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?. Hepatitis Research and Treatment 2010, pages 1-9.
Crossref
Crossref
Melissa A. Cobleigh, Linda Buonocore, Susan L. Uprichard, John K. Rose & Michael D. Robek. (2010) A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose. Journal of Virology 84:15, pages 7513-7522.
Crossref
Crossref
Antonio Bertoletti, Mala K Maini & Carlo Ferrari. (2010) The Host–pathogen Interaction during HBV Infection: Immunological Controversies. Antiviral Therapy 15:3_suppl, pages 15-24.
Crossref
Crossref
Mala K. Maini & Anna Schurich. (2010) The molecular basis of the failed immune response in chronic HBV: Therapeutic implications. Journal of Hepatology 52:4, pages 616-619.
Crossref
Crossref